This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Determine the Safety, Tolerability and Efficacy of KP‑413 in Subjects With Atopic Dermatitis(AD)

This study has been completed.
Sponsor:
Collaborator:
Dow Pharmaceutical Sciences
Information provided by (Responsible Party):
Kaken Pharmaceutical
ClinicalTrials.gov Identifier:
NCT00932074
First received: June 30, 2009
Last updated: April 4, 2012
Last verified: April 2012
  Purpose
The purpose of this study is to assess the safety, tolerability and efficacy of KP‑413 topical ointment compared with vehicle ointment in treating adult subjects with atopic dermatitis (AD).

Condition Intervention Phase
Atopic Dermatitis Drug: KP-413 Ointment Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study Evaluating the Safety, Tolerability and Efficacy of KP-413 Topical Ointment in Subjects With Atopic Dermatitis

Resource links provided by NLM:


Further study details as provided by Kaken Pharmaceutical:

Primary Outcome Measures:
  • Investigator's Global Severity Score(IGSS) [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Plasma levels of KP-413 [ Time Frame: 6 weeks ]
  • Signs and Symptoms of AD [ Time Frame: 4 weeks ]
  • Subject's Numerical Rating Scale(NRS) of Pruritus Score [ Time Frame: 4 weeks ]
  • Percent of AD-affected body surface area (BSA) [ Time Frame: 4 weeks ]

Enrollment: 58
Study Start Date: July 2009
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 3% KP-413 Ointment Drug: KP-413 Ointment
Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
Experimental: 1% KP-413 Ointment Drug: KP-413 Ointment
Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
Placebo Comparator: Placebo Drug: KP-413 Ointment
Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has a clear diagnosis of AD meeting the Hanifin and Rajka criteria for AD that involves both the head/neck and the torso/limbs, and affects 5-30% of the subject's total BSA as determined using the rule of nines
  • Has a Baseline IGSS of 3(moderate) or 4(severe) in the selected treatment area on the torso/limbs, and a Baseline IGSS of 2(mild), 3(moderate) or 4(severe) in the selected treatment area on the head/neck.
  • Female of childbearing potential has a negative pregnancy test and will be using an effective method of contraception during the study.

Exclusion Criteria:

  • Female who is pregnant, nursing an infant, or planning a pregnancy during the study period.
  • Has a Baseline oozing/crusting score of 3(moderate) or greater at the selected treatment area on the head/neck or torso/limbs.
  • Presence of a concurrent skin condition that could interfere with assessment of treatment.
  • Treatment with any investigational drug or device within 30 days or 5 half lives(whichever is longer) prior to the Baseline visit, or concurrent participation in another clinical trial with an investigational drug or device.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00932074

Locations
United States, Michigan
Michigan Center for Research Corp
Clinton Twp., Michigan, United States, 48038
United States, Oregon
Oregon Medical Research Center, PC
Portland, Oregon, United States, 97223
United States, Texas
DermResearch, Inc.
Austin, Texas, United States, 78759
J & S Studies, Inc.
College Station, Texas, United States, 77845
Dermatology Treatment & Research Center, PA
Dallas, Texas, United States, 75230
United States, Virginia
The Education & Research Foundation, Inc
Lynchburg, Virginia, United States, 24501-1604
Sponsors and Collaborators
Kaken Pharmaceutical
Dow Pharmaceutical Sciences
Investigators
Study Director: Barry Calvarese, MS Dow Pharmaceutical Sciences
  More Information

Responsible Party: Kaken Pharmaceutical
ClinicalTrials.gov Identifier: NCT00932074     History of Changes
Other Study ID Numbers: DPSI-KP413-P2-01
Study First Received: June 30, 2009
Last Updated: April 4, 2012

Keywords provided by Kaken Pharmaceutical:
Atopic Dermatitis

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on August 17, 2017